LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Stock List・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Closed

SectorHealthcare

53.68 -1.2

Buy Sell

Overview

Share price change

24h

Current

Min

53.02

Max

54.54

Key metrics
By Trading Economics
Income	3M -102M
EPS	-1.17
Employees	358
EBITDA	-7.6M -112M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+44.09% upside

Dividends
By Dow Jones
Next Earnings	10 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-155M 5.4B
Previous open	54.88
Previous close	53.68

News Sentiment

By Acuity

33%

67%

67 / 345 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

34.81 / 38.24 Support & Resistance

Xenon Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 Mar 2026, 16:12 UTC

Major Market Movers

Xenon Pharmaceuticals Shares Surge on Positive Study Data for Azetukalner

Peer Comparison

Price change

Xenon Pharmaceuticals Inc Forecast

Price Target

By TipRanks

44.09% upside

12 Months Forecast

Average 78.37 USD 44.09%

High 100 USD

Low 55 USD

Based on 19 Wall Street analysts offering 12 month price targets forXenon Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

19 ratings

Buy

Hold

Sell

Based on 19 analysts giving stock ratings to Xenon Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

34.81 / 38.24Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

67 / 345 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.